JP2013534256A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534256A5
JP2013534256A5 JP2013525003A JP2013525003A JP2013534256A5 JP 2013534256 A5 JP2013534256 A5 JP 2013534256A5 JP 2013525003 A JP2013525003 A JP 2013525003A JP 2013525003 A JP2013525003 A JP 2013525003A JP 2013534256 A5 JP2013534256 A5 JP 2013534256A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
compound according
acceptable salt
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013525003A
Other languages
English (en)
Japanese (ja)
Other versions
JP6250394B2 (ja
JP2013534256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048472 external-priority patent/WO2012024616A1/en
Publication of JP2013534256A publication Critical patent/JP2013534256A/ja
Publication of JP2013534256A5 publication Critical patent/JP2013534256A5/ja
Application granted granted Critical
Publication of JP6250394B2 publication Critical patent/JP6250394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013525003A 2010-08-19 2011-08-19 軽度の認知障害(mci)および関連障害の処置方法 Active JP6250394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40190710P 2010-08-19 2010-08-19
US61/401,907 2010-08-19
PCT/US2011/048472 WO2012024616A1 (en) 2010-08-19 2011-08-19 Methods of treating miild cognitive impairment (mci) and related discorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016160482A Division JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害(mci)および関連障害の処置方法

Publications (3)

Publication Number Publication Date
JP2013534256A JP2013534256A (ja) 2013-09-02
JP2013534256A5 true JP2013534256A5 (OSRAM) 2014-10-09
JP6250394B2 JP6250394B2 (ja) 2017-12-20

Family

ID=45605447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013525003A Active JP6250394B2 (ja) 2010-08-19 2011-08-19 軽度の認知障害(mci)および関連障害の処置方法
JP2016160482A Pending JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害(mci)および関連障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016160482A Pending JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害(mci)および関連障害の処置方法

Country Status (10)

Country Link
US (1) US10449177B2 (OSRAM)
EP (1) EP2605655B1 (OSRAM)
JP (2) JP6250394B2 (OSRAM)
AU (1) AU2011291506B2 (OSRAM)
BR (1) BR112013003847A8 (OSRAM)
CA (1) CA2808630A1 (OSRAM)
DK (1) DK2605655T3 (OSRAM)
ES (1) ES2705027T3 (OSRAM)
MX (1) MX353096B (OSRAM)
WO (1) WO2012024616A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
WO2014025905A1 (en) 2012-08-07 2014-02-13 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
AU2016220049C1 (en) 2015-02-18 2021-02-25 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
JP2018516901A (ja) * 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーSynaptec Development Llc アミロイドβのガランタミンクリアランス
PL3347002T3 (pl) * 2015-09-10 2023-11-13 Alzheon, Inc. Leczenie choroby alzheimera w konkretnej populacji pacjentów
US10441573B2 (en) 2015-12-09 2019-10-15 Brandeis University DBH inhibitors for treating memory loss
US20180250249A1 (en) * 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population
US20190134000A1 (en) 2016-05-12 2019-05-09 Buck Institute For Research On Aging Compounds to promote normal processing of app
EP3565846A4 (en) 2017-01-03 2020-01-22 Bioatla, LLC PROTEIN THERAPEUTICS FOR THE TREATMENT OF SENESCENT CELLS
IL312612A (en) 2018-07-11 2024-07-01 Rubedo Life Sciences Inc Senolytic compositions and uses thereof
CN110232679A (zh) * 2019-05-24 2019-09-13 潘丹 一种阿尔茨海默症遗传生物标志物确定方法及系统
EP4005566B1 (en) 2019-07-25 2024-10-30 Tokyo University of Science Foundation Disulfiram and related compounds for treating, preventing or improving anxiety disorders or symptoms, and depressive disorders or symptoms

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
CA2085127C (en) 1990-06-15 2002-12-10 Barbara Cordell Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
DE69233774D1 (de) 1991-01-21 2009-12-10 Elan Pharm Inc Prüfung und Modell für Alzheimers-Krankheit
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
CA2127450C (en) 1992-01-07 2007-04-17 Samuel Wadsworth Transgenic animal models for alzheimer's disease
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ES2155099T3 (es) 1993-10-27 2001-05-01 Elan Pharm Inc Animales transgenicos que albergan alelos app que presentan una mutacion sueca.
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1996040885A2 (en) 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
CN1198936C (zh) 1998-09-24 2005-04-27 法玛西雅厄普约翰美国公司 阿尔茨海默氏疾病分泌酶
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
WO2000059863A1 (en) 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US20040092511A1 (en) 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020115727A1 (en) 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
FR2846559B1 (fr) 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
AU2005217320B2 (en) 2004-02-26 2011-07-21 Aska Pharmaceuticals Co., Ltd. Pyrimidine derivative
AU2005235162B2 (en) 2004-04-21 2010-11-18 Mear Holding B.V. System for measuring pulsatile vascular resistance
EP1741430B1 (en) 2004-04-30 2009-07-15 National University Corporation Chiba University Remedy for psychoneurotic diseases
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
CA2590802A1 (en) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
DE602005019210D1 (de) 2004-12-23 2010-03-18 Xenoport Inc Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon
EP1885708A2 (en) 2005-04-15 2008-02-13 Board of Trustees of Michigan State University Gpcr modulators
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP1993542A1 (en) 2006-03-01 2008-11-26 Galderma Research & Development, S.N.C. Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 n-(메틸)-1h-피라졸-3-아민, n-(메틸)-피리딘-2-아민 및 n-(메틸)-티아졸-2-아민 유도체
WO2008074896A1 (en) * 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
EP2933243B1 (en) 2007-05-03 2017-11-01 Jack L. Arbiser Honokiol analogs and their use in treating cancers
EP2219449A4 (en) 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
CL2007003877A1 (es) 2007-12-28 2008-06-27 Univ De Concepcion Lab Androma Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina.
ES2527448T3 (es) 2008-04-28 2015-01-23 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
EP2310019A4 (en) 2008-05-29 2011-06-01 Albany Molecular Res Inc 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE
JP5514827B2 (ja) 2008-09-25 2014-06-04 バイオランド リミテッド 4−o−メチルホノキオールを含有するアミロイド関連疾患の治療又は予防用組成物
CN102307574A (zh) 2008-10-08 2012-01-04 鲍斯生命科学Pvt有限公司 缓释给药系统
US20100099701A1 (en) 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
CN101444508B (zh) 2008-12-29 2010-10-27 海南瑞基药物研究有限公司 一种注射用托烷司琼制剂及其制备方法
EP2432437A4 (en) 2009-05-21 2012-12-19 Bionex Pharmaceuticals Llc TWO- AND ONE-LAYER DOSAGE FORMS
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US9790109B2 (en) * 2010-04-30 2017-10-17 General Electric Company Method for sanitizing an electrodeionization device
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
WO2013123426A1 (en) 2012-02-18 2013-08-22 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions

Similar Documents

Publication Publication Date Title
JP2013534256A5 (OSRAM)
JP7627514B2 (ja) R-ケタミンおよびその塩の医薬品としての応用
JP2017075173A5 (OSRAM)
JP2015510941A5 (OSRAM)
JP2018035197A5 (OSRAM)
FI3478712T3 (fi) Anti-N3pGlu beeta-amyloidipeptidi -vasta-aineita ja niiden käyttöjä
JP2013533287A5 (OSRAM)
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2012530723A5 (OSRAM)
US10342807B2 (en) Pharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201400183A1 (ru) Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства
JP2011504474A5 (OSRAM)
WO2020222799A1 (en) A method of treating mental, behavioral, cognitive disorders
RU2016102092A (ru) Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
WO2011058262A1 (fr) Médicament inhalable à base de xénon pour traiter ou pour prévenir les dyskinésies induites
JP2009178162A5 (OSRAM)
Zhang et al. N-butylphthalide affects cognitive function of APP/PS1 transgenic mice (Alzheimer’s disease model)
CA3138389A1 (en) Rebamipide for use in prevention and/or treatment of synucleinopathies
JP2016528171A5 (OSRAM)
JP2020527172A5 (OSRAM)
RU2019101210A (ru) Производное оксазина для применения в предупреждении болезни альцгеймера у пациентов, находящихся в группе риска
EP3137097A1 (en) Treatment and prevention of alzheimer's disease (ad)
WO2007005940A2 (en) Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders